Scientists have discovered that an enzyme can rid cells of a gene believed to be responsible for a wide range of cancers.
Dr Jorg Hartkamp and Dr Stefan Roberts have found that the protease HtrA2 can "clean" cells of the oncogene WT1, which is found at high levels in many leukaemias and solid cancers such as breast and lung cancer.
Their work has given drug designers a new target which will allow them to develop treatments for all these cancers in which WT1 expression is elevated.
WT1 is a well-known factor in cancer, having been discovered 20 years ago. It suppresses the development of Wilms' tumour of the kidney, a rare cancer that affects one in 10,000 children. However it has a cancer causing role in other forms of the disease, particularly leukemias such as acute myeloid leukaemia (AML) and chronic myeloid leukaemia (CML).
In addition high expression of WT1 is associated with a bad prognosis in AML patients, while trials using peptide vaccines against WT1 in patients with lung cancer, breast cancer and leukaemia were promising.
This latest study -- published in the journal Molecular Cell and funded by the Wellcome Trust, Cancer Research UK and the Association of International Cancer Research (AICR) -- is the first to identify the enzyme that can rid cells of WT1.
Dr Hartkamp, at the University of Manchester's Faculty of Life Sciences, said: "The cancer causing role of WT1 has been known for many years, but how it worked was not understood so we studied a regulatory domain of WT1 to see what modified its activity. We carried out a fishing experiment and discovered the role of the protease HtrA2 instead, by accident. This discovery has a much bigger impact.
"We have filled in the black box of WT1. It is this protease that is doing the trick -- it can clean cells of WT1."
Dr Roberts, who initiated the work at Manchester and is now at the University at Buffalo, added: "There are great prognostic implications in leukaemias but this protease may have even more targets. It is unlikely that a protease cleaves only one transcription factor such as WT1."
Dr Lesley Walker, director of cancer information at Cancer Research UK, said: "This research sheds new light about how levels of WT1 are controlled and will help us understand more about its role in cancer. Although still at an early stage, this research is an exciting advance and could help to improve the treatment of types of cancer where WT1 is known to have an influence."
AICR's Scientific Adviser Dr Mark Matfield said: "This exciting new finding shows why it is so important to carry out basic research into cancer. More and more these days, we see basic research discovering something unexpected about cancer that could be a major new step forward. The more we find out about cancer the closer we get to beating it."
The team plans to study HtrA2 further, to find out how it is inactivated in cancer cells (allowing WT1 to proliferate) and what other targets HtrA2 has. This will help pharmaceutical companies design a drug to reactivate HtrA2 and apply the protease to different diseases.
It is hoped that patients will be screened for a high level of WT1 and, if this is the case, clinicians can reactivate HtrA2. And as WT1 expression is low in healthy adults, oncogenic expression of WT1 has been found to be tumour specific so targeting WT1 will be less damaging to the patient's general health.
The paper 'The Wilms' Tumour Suppressor Protein WT1 is processed by the serine protease HtrA2/Omi' is available at http://www.cell.com/molecular-cell/fulltext/S1097-2765(09)00954-X
- Jörg Hartkamp, Brian Carpenter, Stefan G.E. Roberts. The Wilms' Tumor Suppressor Protein WT1 Is Processed by the Serine Protease HtrA2/Omi. Molecular Cell, Volume 37, Issue 2, 159-171, 29 January 2010 DOI: 10.1016/j.molcel.2009.12.023
Cite This Page: